Drug Class Review: Constipation Drugs: Final Report [Internet]

Gerald Gartlehner; Daniel E Jonas; Laura C Morgan; Yehuda Ringel; Richard A Hansen; Curtis M Bryant; Tim Carey

Drug Class Review: Constipation Drugs: Final Report [Internet]

Review

Portland (OR): Oregon Health & Science University; 2007 Sep.

Drug Class Reviews.

Authors

Gerald Gartlehner¹, Daniel E Jonas¹, Laura C Morgan¹, Yehuda Ringel¹, Richard A Hansen¹, Curtis M Bryant¹, Tim Carey¹

Affiliation

¹ RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, 725 Martin Luther King Jr. Blvd, CB# 7590, Chapel Hill, NC 27599-7590, Tim Carey, MD, MPH, Director

PMID: 20496364
Bookshelf ID: NBK10503

Excerpt

Chronic constipation is a disorder characterized by unsatisfactory defecation that results from infrequent stools, difficult stool passage, or both over a time period of at least 12 weeks. In this report, we review the general and comparative effectiveness, safety, and tolerability of drugs for chronic constipation. Our review covers the use of the following in adults and children with chronic constipation and Irritable Bowel Syndrome, constipation-predominant (IBS-C): docusate calcium, docusate sodium, lactulose, lubiprostone, polyethylene glycol 3350, psyllium, and tegaserod.

Sections

Publication types

Review

Grants and funding

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.